Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860055 | 1.00 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL2947235 | 0.94 | ALDH1A1 (0.63) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL230222 | 0.91 | CHRM2 (0.70) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL29438821 | 0.91 | CHRM2 (0.70) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL5892980 | 0.91 | NPC1 (0.55) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL3906840 | 0.91 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL12963429 | 0.91 | RAB9A (0.57) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL19416501 | 0.91 | TP53 (0.61) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL3316286 | 0.91 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A | |
| SCHEMBL8346148 | 0.91 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1CHRM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003524620-A | — | — | 2003-08-19 | — | — | JP | claimed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | claimed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4143302-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO | Magenta Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021222313-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO | Magenta Therapeutics, Inc. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3720494-A2 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | Magenta Therapeutics, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2019113375-A2 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | Magenta Therapeutics, Inc. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| WO-2007106063-A2 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1796716-A2 | CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2007-06-20 | — | — | EP | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| WO-2006020891-A2 | CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2006-02-23 | — | — | WO | disclosed |
| EP-1411918-A2 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011277-A2 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2003-02-13 | — | — | WO | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | L3MBTL1 2706/4885ALDH1A1 3626/4885CHRM2 1502/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | L3MBTL1 2706/4885ALDH1A1 3626/4885CHRM2 1502/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | L3MBTL1 1582/4885ALDH1A1 1269/4885CHRM2 2020/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | L3MBTL1 2706/4885ALDH1A1 3626/4885CHRM2 1502/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | L3MBTL1 2706/4885ALDH1A1 3626/4885CHRM2 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.